View Author
patient cancer lymph prognostic tumor base model breast model dataset status breast cancer urokinase-type plasminogen activator analysis lymph node status curve plasminogen lymph node-positive patients activator level factor node-negative <.001 value lymph node-negative patients survival adjuvant treatment variable hormone-receptor status study cancer institute prognostic factors prognostic value adjuvant treatment inhibitor multivariable breast cancer patients table lymph node-negative grade urokinase-type number group result prognostic variables 10 years menopausal status analyses histologic grade hazard effect node-positive institute hormone-receptor assay prognostic score marker article 120 months tumor size january difference prognosis journal event ratio month urokinase plasminogen activator system addition method therapy likelihood ratio test relapse-free survival histologic score subgroups relapse-free laboratory tumor characteristics
5 Most Recent Publications
|
Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk
(Article)
Tilanus-Linthorst, M.M.A. Roozenbeek, B. Eeles, R. Oosterwijk, J.C. Leach, M.O. Steyerberg, E.W. Evans, D.G. Thompson, D. Kaas, R. Manders, P. Asperen, C.J. van Adank, M.A. Hooning, M. Kwan Lim, G.E. |
2013-07-01
|
|
Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers
(Article)
Pijpe, A. Manders, P. Aalfs, C. Veer, L.J. van 't Gómez García, E.B. Leeuwen, F.E. van Rookus, M.A. Brohet, R.M. Collee, J.M. Verhoef, S. Vasen, H. Hoogerbrugge, N. Asperen, C.J. van Dommering, C.J. Ausems, M.G.E.M. |
2010-02-01
|
|
Body weight and risk of breast cancer in BRCA1/2 mutation carriers
(Article)
Manders, P. Pijpe, A. Gomez-Garcia, E.B. Brohet, R.M. Leeuwen, F.E. van Rookus, M.A. Hooning, M. Kluijt, I. Vasen, H.F. Hoogerbrugge, N. Asperen, C.J. van Meijers-Heijboer, H. Ausems, M.G.E.M. Os, T.A.M. van |
2010-01-01
|
|
Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
(Article)
Antoniou, A.C. Spurdle, A.B. Hofmann, W. Sutter, C. Niederacher, D. Deissler, H. Caldes, T. Kämpjärvi, K. Nevanlinna, H. Simard, J. Beesley, J. Chen, X. Sinilnikova, O. Neuhausen, S.L. Rebbeck, T.R. Wagner, T. Lynch, H. Isaacs, C. Weitzel, J. Ganz, P.A. Daly, M. Tomlinson, G. Olopade, O.I. Healey, S. Blum, J.L. Couch, F.J. Peterlongo, P. Manoukian, S. Barile, M. Radice, P. Szabo, C. Pereira, L.H.M. Greene, M.H. Rennert, G. Pooley, K.A. Lejbkowicz, F. Barnett-Griness, O. Andrulis, I.L. Ozcelik, H. Gerdes, A-M. Caligo, M.A. Laitman, Y. Kaufman, B. Milgrom, R. Friedman, E. Schmutzler, R.K. Domchek, S.M. Nathanson, K.L. Osorio, A. Llort, G. Milne, R.L. Benítez, J. Hamann, U. Hogervorst, F.B.L. Manders, P. Ligtenberg, M. Versmold, B. Ouweland, A.M.W. van den Peock, S. Cook, M. Platte, R. Evans, D.G. Eeles, R. Pichert, G. Chu, C. Eccles, D. Davidson, R. Engel, C. Douglas, F. Godwin, A.K. Barjhoux, L. Mazoyer, S. Sobol, H. Bourdon, V. Eisinger, F. Chompret, A. Capoulade, C. Bressac-de Paillerets, B. Meindl, A. Lenoir, G.M. Gauthier-Villars, M. Houdayer, C. Stoppa-Lyonnet, D. Chenevix-Trench, G. Easton, D.F. Arnold, N. |
2008-04-11
|
|
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
(Article)
Look, M.P. Kueng, W. Kates, R. Magdelenat, H. Martin, P.M. Beex, L.V. Windbichler, G. Janicke, F. Spyratos, F. Peyrat , J.P. Ricolleau, G. Cufer, T. Klijn, J.G.M. Brunner, N. Meijer van Gelder, M.E. Bendahl, P.O. Ulm, K. Schmitt, M. Eppenberger-Castori, S. Sweep, C.G. Fiets, W.E. Duggan, C. Blankenstein, M.A. Broet, P. Borstnar, S. Daxenbichler, G. Foekens, J.A. O'Higgins, N. Duffy, M.J. Daver, A. Manders, P. Romain, S. Quillien, V. Harbeck, N. Eppenberger, U. Putten, W.L.J. van Ferno, M. Christensen, I.J. Lisboa, B.W. Thomssen, C. |
2002-01-16
|
